1iSnijders PJ, Steenbergen RD, Heideman DA, et al. HPV-mediated cervical carcinogenesis: concepts and clinical implications [ J ]. J Pathol, 2006,208(2) : 152-164.
2Wu Y, Chen Y, Li L, et al. Associations of high-risk I-IPV types and viral load with cervical cancer in China [ J ]. J Clin Virol, 2006,35(3) :264-9.
3Patricia C,Anne R, Alexia S, et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype [ J ]. International Journal of Cancer, 2009, 124 (4) :778-782.
6Kang YH, Lee KA, Ryu CJ, et al. Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cer- vical carcinoma cells[ J]. Cancer Letters, 2006,237 (1) : 33-44.
7De Cremoux P, De La Rochefordi:re A, Savignoni A, et al. Differ- ent outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype[J]. Int J Cancer, 2009, 124(4) :778-782.
8Kawana K, Yasugi T, Taketani Y. Human papillomavirus vaccines: current issues & future[J] .Indian J Med Res,2009,130(3) :341- 347.
9Veatad I T, Gudlaugsson E, Ivar S, et al. Local immune response of CIN2-3 with and without spontaneous regression[ J ]. Modem Pathology, 2010,23 ( 9 ) : 1 - 10.
10Bekkers B L, Massuger L F, Bumen J, et al. Epidemiological clini- cal aspects othuman papillomavirus detection in the prevention of cervical cancer[J]. Rev IVied Virol,2004,14:95.
